How will MIRIADE accelerate the development of biomarker tools for dementia?Read More
Dementia is a deterioration in cognitive abilities affecting areas including memory, language skills, perception, reasoning, and problem-solving. It can also be accompanied by an associated decline in behavioural abilities related to emotional control, social behaviour, or motivation. Around 50 million people worldwide suffer from dementia and there are approximately 10 million new cases each year. Despite the widespread prevalence and debilitating effects of dementia, there are currently no reliable tests to detect the underlying pathophysiology years before the symptoms begin. MIRIADE is working on changing that with the help of a new generation of researchers. The focus is on biomarker discovery and clinical validation, including addressing regulatory requirements. Early diagnosis will significantly enhance options for monitoring and modulating progression.